The following is a summary of “Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...

Learn about the Academy's advocacy priorities and how to join efforts to protect your practice.

Contrary to some commonly held beliefs, current research shows that cutting out certain foods makes little difference in ...